Safety and pharmacokinetics of the CIME combination of drugs and their metabolites after a single oral dosing in healthy volunteers

  • Natacha Lenuzza
  • Xavier Duval
  • Grégory Nicolas
  • Etienne Thévenot
  • Sylvie Job
  • Orianne Videau
  • Céline Narjoz
  • Marie-Anne Loriot
  • Philippe Beaune
  • Laurent Becquemont
  • France Mentré
  • Christian Funck-Brentano
  • Loubna Alavoine
  • Philippe Arnaud
  • Marcel Delaforge
  • Henri Bénech
Original Paper
First Online:
Received:
Accepted:

Abstract

This phase I, pilot clinical study was designed to evaluate the safety and the pharmacokinetic (PK) profiles of the CIME (Metabolic Identity Card) combination of ten drugs, with a view to its use as a phenotyping cocktail. Ten healthy Caucasian subjects were orally dosed with the CIME combination (caffeine–CYP1A2, repaglinide–CYP2C8, tolbutamide–CYP2C9, omeprazole–CYP2C19, dextromethorphan–CYP2D6, midazolam–CYP3A, acetaminophen–UGT1A1, 6&9 and 2B15, digoxin–P-gp, rosuvastatin–OATP1B1&3 and memantine–active renal transport). Blood was collected over 3 days and on day 7. CIME probes and relevant metabolites were assayed by LC–MS/MS and PK parameters were calculated. Main results were: (1) good safety with reversible mild or moderate adverse effects, (2) an analytical method able to quantify simultaneously the 10 probes and the major metabolites, (3) calculation of PK parameters for all probes in general agreed with published values, and (4) identification of the low CYP2D6 metabolizer. This pilot study showed that the CIME combination was well tolerated and that its pharmacokinetics could be accurately measured in healthy volunteers. This combination can now confidently be checked for sensitivity and specificity and for lack of interaction to be validated as a phenotyping cocktail.

Keywords

CIME Probes Phase I Pharmacokinetics Safety 
This is a preview of subscription content, log in to check access.

Notes

Conflict of interest

The authors declare no conflict of interest.

Supplementary material

13318_2014_239_MOESM1_ESM.docx (544 kb)
Supplementary material 1 (DOCX 544 kb)

References

  1. Allegaert K, Vanhaesebrouck S, Verbesselt R, van den Anker JN (2009) In vivo glucuronidation activity of drugs in neonates: extensive interindividual variability despite their young age. Ther Drug Monit 31:411–415CrossRefPubMedGoogle Scholar
  2. Bauman JL, Didomenico RJ, Galanter WL (2006) Mechanisms, manifestations, and management of digoxin toxicity in the modern era. Am J Cardiovasc Drugs 6:77–86CrossRefPubMedGoogle Scholar
  3. Borges S, Li L, Hamman MA, Jones DR, Hall SD, Gorski JC (2005) Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance. Drug Metab Dispos 33:1052–1055CrossRefPubMedGoogle Scholar
  4. Bornemann LD, Min BH, Crews T, Rees MM, Blumenthal HP, Colburn WA, Patel IH (1985) Dose dependent pharmacokinetics of midazolam. Eur J Clin Pharmacol 29:91–95CrossRefPubMedGoogle Scholar
  5. Breimer DD, Schellens JH (1990) A ‘cocktail’ strategy to assess in vivo oxidative drug metabolism in humans. Trends Pharmacol Sci 11:223–225CrossRefPubMedGoogle Scholar
  6. Bruce MA, Hall SD, Haehner-Daniels BD, Gorski JC (2001) In vivo effect of clarithromycin on multiple cytochrome P450s. Drug Metab Dispos 29:1023–1028PubMedGoogle Scholar
  7. Calabresi L, Pazzucconi F, Ferrara S, Di Paolo A, Tacca MD, Sirtori C (2004) Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers. Pharmacol Res 49:493–499CrossRefPubMedGoogle Scholar
  8. Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, Zhang Y, Kashuba AD, Rowland E, Bertino JS Jr (2003) Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the “Cooperstown 5 + 1 cocktail”. Clin Pharmacol Ther 74:437–447CrossRefPubMedGoogle Scholar
  9. Choi JH, Lee MG, Cho JY, Lee JE, Kim KH, Park K (2008) Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clin Pharmacol Ther 83:251–257CrossRefPubMedGoogle Scholar
  10. Chowbay B, Li H, David M, Cheung YB, Lee EJ (2005) Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol 60:159–171CrossRefPubMedPubMedCentralGoogle Scholar
  11. Combes FP, Retout S, Frey N, Mentre F (2013) Prediction of shrinkage of individual parameters using the bayesian information matrix in non-linear mixed effect models with evaluation in pharmacokinetics. Pharm Res 30:2355–2367CrossRefPubMedGoogle Scholar
  12. Corona G, Vaccher E, Sandron S, Sartor I, Tirelli U, Innocenti F, Toffoli G (2008) Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi’s sarcoma. Clin Pharmacol Ther 83:601–606CrossRefPubMedGoogle Scholar
  13. Court MH (2005) Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. Methods Enzymol 400:104–116CrossRefPubMedGoogle Scholar
  14. Court MH, Duan SX, von Moltke LL, Greenblatt DJ, Patten CJ, Miners JO, Mackenzie PI (2001) Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther 299:998–1006PubMedGoogle Scholar
  15. Critchley JA, Critchley LA, Anderson PJ, Tomlinson B (2005) Differences in the single-oral-dose pharmacokinetics and urinary excretion of paracetamol and its conjugates between Hong Kong Chinese and Caucasian subjects. J Clin Pharm Ther 30:179–184CrossRefPubMedGoogle Scholar
  16. Derks M, Fowler S, Kuhlmann O (2009) In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates. Curr Med Res Opin 25:891–902CrossRefPubMedGoogle Scholar
  17. Doroshyenko O, Rokitta D, Zadoyan G, Klement S, Schlafke S, Dienel A, Gramatte T, Luck H, Fuhr U (2013) Drug cocktail interaction study on the effect of the orally administered lavender oil preparation silexan on cytochrome P450 enzymes in healthy volunteers. Drug Metab Dispos 41:987–993CrossRefPubMedGoogle Scholar
  18. Dumond JB, Vourvahis M, Rezk NL, Patterson KB, Tien HC, White N, Jennings SH, Choi SO, Li J, Wagner MJ, La-Beck NM, Drulak M, Sabo JP, Castles MA, Macgregor TR, Kashuba AD (2010) A phenotype–genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther 87:735–742CrossRefPubMedPubMedCentralGoogle Scholar
  19. Evans WE, Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487–491CrossRefPubMedGoogle Scholar
  20. Fan L, Zhang W, Guo D, Tan ZR, Xu P, Li Q, Liu YZ, Zhang L, He TY, Hu DL, Wang D, Zhou HH (2008) The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1. Clin Pharmacol Ther 83:471–476CrossRefPubMedGoogle Scholar
  21. Freudenthaler S, Meineke I, Schreeb KH, Boakye E, Gundert-Remy U, Gleiter CH (1998) Influence of urine pH and urinary flow on the renal excretion of memantine. Br J Clin Pharmacol 46:541–546CrossRefPubMedPubMedCentralGoogle Scholar
  22. Frye RF, Matzke GR, Adedoyin A, Porter JA, Branch RA (1997) Validation of the five-drug “Pittsburgh cocktail” approach for assessment of selective regulation of drug-metabolizing enzymes. Clin Pharmacol Ther 62:365–376CrossRefPubMedGoogle Scholar
  23. Fuhr U, Jetter A, Kirchheiner J (2007) Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the “cocktail” approach. Clin Pharmacol Ther 81:270–283CrossRefPubMedGoogle Scholar
  24. Guevart E, Aguemon A (2009) Two cases of fulminant hepatitis during a curative treatment with an artesunate-amodiaquine combination. Med Mal Infect 39:57–60CrossRefPubMedGoogle Scholar
  25. Iusuf D, van de Steeg E, Schinkel AH (2012) Functions of OATP1A and 1B transporters in vivo: insights from mouse models. Trends Pharmacol Sci 33:100–108CrossRefPubMedGoogle Scholar
  26. Jetter A, Fatkenheuer G, Frank D, Klaassen T, Seeringer A, Doroshyenko O, Kirchheiner J, Hein W, Schomig E, Fuhr U, Wyen C (2010) Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients? Antivir Ther 15:975–983CrossRefPubMedGoogle Scholar
  27. Jones AE, Brown KC, Werner RE, Gotzkowsky K, Gaedigk A, Blake M, Hein DW, van der Horst C, Kashuba AD (2010) Variability in drug metabolizing enzyme activity in HIV-infected patients. Eur J Clin Pharmacol 66:475–485CrossRefPubMedPubMedCentralGoogle Scholar
  28. Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M (2008) No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. Br J Clin Pharmacol 65:78–86CrossRefPubMedPubMedCentralGoogle Scholar
  29. Kiley CA, Cragin DJ, Roth BJ (2007) Omeprazole-associated digoxin toxicity. South Med J 100:400–402CrossRefPubMedGoogle Scholar
  30. Kirchheiner J, Bauer S, Meineke I, Rohde W, Prang V, Meisel C, Roots I, Brockmoller J (2002) Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 12:101–109CrossRefPubMedGoogle Scholar
  31. Kita T, Sakaeda T, Aoyama N, Sakai T, Kawahara Y, Kasuga M, Okumura K (2002) Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations. Biol Pharm Bull 25:923–927CrossRefPubMedGoogle Scholar
  32. Lacombe O, Videau O, Chevillon D, Guyot AC, Contreras C, Blondel S, Nicolas L, Ghettas A, Benech H, Thevenot E, Pruvost A, Bolze S, Krzaczkowski L, Prevost C, Mabondzo A (2011) In vitro primary human and animal cell-based blood-brain barrier models as a screening tool in drug discovery. Mol Pharm 8:651–663CrossRefPubMedGoogle Scholar
  33. Lappin G, Shishikura Y, Jochemsen R, Weaver RJ, Gesson C, Brian Houston J, Oosterhuis B, Bjerrum OJ, Grynkiewicz G, Alder J, Rowland M, Garner C (2011) Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers. Eur J Pharm Sci 43:141–150CrossRefPubMedGoogle Scholar
  34. Lee LS, Pham P, Flexner C (2012) Unexpected drug–drug interactions in human immunodeficiency virus (HIV) therapy: induction of UGT1A1 and bile efflux transporters by Efavirenz. Ann Acad Med Singap 41:559–562PubMedGoogle Scholar
  35. Martin PD, Warwick MJ, Dane AL, Hill SJ, Giles PB, Phillips PJ, Lenz E (2003) Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 25:2822–2835CrossRefPubMedGoogle Scholar
  36. Miners JO, Mackenzie PI, Knights KM (2010) The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metab Rev 42:196–208CrossRefPubMedGoogle Scholar
  37. Miners JO, Knights KM, Houston JB, Mackenzie PI (2006) In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem Pharmacol 71:1531–1539CrossRefPubMedGoogle Scholar
  38. Miners JO, Smith PA, Sorich MJ, McKinnon RA, Mackenzie PI (2004) Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu Rev Pharmacol Toxicol 44:1–25CrossRefPubMedGoogle Scholar
  39. Navarro SL, Chen Y, Li L, Li SS, Chang JL, Schwarz Y, King IB, Potter JD, Bigler J, Lampe JW (2011) UGT1A6 and UGT2B15 polymorphisms and acetaminophen conjugation in response to a randomized, controlled diet of select fruits and vegetables. Drug Metab Dispos 39:1650–1657CrossRefPubMedPubMedCentralGoogle Scholar
  40. Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, Eichelbaum M, Kivisto KT, Neuvonen PJ (2005) Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 77:468–478CrossRefPubMedGoogle Scholar
  41. Noetzli M, Guidi M, Ebbing K, Eyer S, Wilhelm L, Michon A, Thomazic V, Alnawaqil AM, Maurer S, Zumbach S, Giannakopoulos P, von Gunten A, Csajka C, Eap CB (2013) Population pharmacokinetic study of memantine: effects of clinical and genetic factors. Clin Pharmacokinet 52:211–223CrossRefPubMedGoogle Scholar
  42. Oosterhuis B, Jonkman JH, Andersson T, Zuiderwijk PB, Jedema JN (1991) Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br J Clin Pharmacol 32:569–572CrossRefPubMedPubMedCentralGoogle Scholar
  43. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M (2007) Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 82:726–733CrossRefPubMedGoogle Scholar
  44. Prot JM, Videau O, Brochot C, Legallais C, Benech H, Leclerc E (2011) A cocktail of metabolic probes demonstrates the relevance of primary human hepatocyte cultures in a microfluidic biochip for pharmaceutical drug screening. Int J Pharm 408:67–75CrossRefPubMedGoogle Scholar
  45. Prueksaritanont T, Chu X, Evers R, Klopfer SO, Caro L, Kothare PA, Dempsey C, Rasmussen S, Houle R, Chan G, Cai X, Valesky R, Fraser IP, Stoch SA (2014) Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin. Br J Clin Pharmacol 78:587–598CrossRefPubMedPubMedCentralGoogle Scholar
  46. Rendic S (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34:83–448CrossRefPubMedGoogle Scholar
  47. Ryu JY, Song IS, Sunwoo YE, Shon JH, Liu KH, Cha IJ, Shin JG (2007) Development of the “Inje cocktail” for high-throughput evaluation of five human cytochrome P450 isoforms in vivo. Clin Pharmacol Ther 82:531–540CrossRefPubMedGoogle Scholar
  48. Saint-Marcoux F, Guigonis V, Decramer S, Gandia P, Ranchin B, Parant F, Bessenay L, Libert F, Harambat J, Bouchet S, Broux F, Compagnon P, Marquet P (2011) Development of a Bayesian estimator for the therapeutic drug monitoring of mycophenolate mofetil in children with idiopathic nephrotic syndrome. Pharmacol Res 63:423–431CrossRefPubMedGoogle Scholar
  49. Sall C, Houston JB, Galetin A (2012) A comprehensive assessment of repaglinide metabolic pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearance. Drug Metab Dispos 40:1279–1289CrossRefPubMedGoogle Scholar
  50. Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA (2013) Applications of CYP450 testing in the clinical setting. Mol Diagn Ther 17:165–184CrossRefPubMedPubMedCentralGoogle Scholar
  51. Schwarz UI (2003) Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Invest 33(Suppl 2):23–30CrossRefPubMedGoogle Scholar
  52. Stewart NA, Buch SC, Conrads TP, Branch RA (2011) A UPLC-MS/MS assay of the “Pittsburgh cocktail”: six CYP probe-drug/metabolites from human plasma and urine using stable isotope dilution. Analyst 136:605–612CrossRefPubMedPubMedCentralGoogle Scholar
  53. Tomalik-Scharte D, Maiter D, Kirchheiner J, Ivison HE, Fuhr U, Arlt W (2010) Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. Eur J Endocrinol 163:919–924CrossRefPubMedPubMedCentralGoogle Scholar
  54. Uchida S, Yamada H, Li XD, Maruyama S, Ohmori Y, Oki T, Watanabe H, Umegaki K, Ohashi K, Yamada S (2006) Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J Clin Pharmacol 46:1290–1298CrossRefPubMedGoogle Scholar
  55. van de Steeg E, van Esch A, Wagenaar E, Kenworthy KE, Schinkel AH (2013) Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice. Clin Cancer Res 19:821–832CrossRefPubMedGoogle Scholar
  56. Varma MV, Lai Y, Kimoto E, Goosen TC, El-Kattan AF, Kumar V (2013) Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide. Pharm Res 30:1188–1199CrossRefPubMedGoogle Scholar
  57. Videau O, Pitarque S, Troncale S, Hery P, Thevenot E, Delaforge M, Benech H (2012) Can a cocktail designed for phenotyping pharmacokinetics and metabolism enzymes in human be used efficiently in rat? Xenobiotica 42:349–354CrossRefPubMedGoogle Scholar
  58. Videau O, Delaforge M, Levi M, Thevenot E, Gal O, Becquemont L, Beaune P, Benech H (2010) Biochemical and analytical development of the CIME cocktail for drug fate assessment in humans. Rapid Commun Mass Spectrom 24:2407–2419CrossRefPubMedGoogle Scholar
  59. Volak LP, Hanley MJ, Masse G, Hazarika S, Harmatz JS, Badmaev V, Majeed M, Greenblatt DJ, Court MH (2013) Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers. Br J Clin Pharmacol 75:450–462CrossRefPubMedPubMedCentralGoogle Scholar
  60. Wohlfarth A, Naue J, Lutz-Bonengel S, Dresen S, Auwarter V (2012) Cocktail approach for in vivo phenotyping of 5 major CYP450 isoenzymes: development of an effective sampling, extraction, and analytical procedure and pilot study with comparative genotyping. J Clin Pharmacol 52:1200–1214CrossRefPubMedGoogle Scholar
  61. Wyen C, Fuhr U, Frank D, Aarnoutse RE, Klaassen T, Lazar A, Seeringer A, Doroshyenko O, Kirchheiner JC, Abdulrazik F, Schmeisser N, Lehmann C, Hein W, Schomig E, Burger DM, Fatkenheuer G, Jetter A (2008) Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clin Pharmacol Ther 84:75–82CrossRefPubMedGoogle Scholar
  62. Zhang W, Yu BN, He YJ, Fan L, Li Q, Liu ZQ, Wang A, Liu YL, Tan ZR, Fen J, Huang YF, Zhou HH (2006) Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta 373:99–103CrossRefPubMedGoogle Scholar
  63. Blickle JF (2006) Meglitinide analogues: a review of clinical data focused on recent trials. Diabetes Metab 32:113–120CrossRefPubMedGoogle Scholar
  64. Gross AS, Bridge S, Shenfield GM (1999) Pharmacokinetics of tolbutamide in ethnic Chinese. Br J Clin Pharmacol 47:151–156CrossRefPubMedPubMedCentralGoogle Scholar
  65. Jetter A, Kinzig-Schippers M, Skott A, Lazar A, Tomalik-Scharte D, Kirchheiner J, Walchner-Bonjean M, Hering U, Jakob V, Rodamer M, Jabrane W, Kasel D, Brockmoller J, Fuhr U, Sorgel F (2004) Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. Eur J Clin Pharmacol 60:165–171CrossRefPubMedGoogle Scholar
  66. Jodynis-Liebert J, Flieger J, Matuszewska A, Juszczyk J (2004) Serum metabolite/caffeine ratios as a test for liver function. In J Clin Pharmacol 44:338–347CrossRefGoogle Scholar
  67. Kamimori GH, Karyekar CS, Otterstetter R, Cox DS, Balkin TJ, Belenky GL, Eddington ND (2002) The rate of absorption and relative bioavailability of caffeine administered in chewing gum versus capsules to normal healthy volunteers. Int J Pharm 234:159–167CrossRefPubMedGoogle Scholar
  68. Lam YW, Alfaro CL, Ereshefsky L, Miller M (2003) Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. In J Clin Pharmacol. 43:1274–1282CrossRefGoogle Scholar
  69. Larsen F, Priskorn M, Overo KF (2001) Lack of citalopram effect on oral digoxin pharmacokinetics. J Clin Pharmacol 41:340–346CrossRefPubMedGoogle Scholar
  70. Liu MY, Meng SN, Wu HZ, Wang S, Wei MJ (2008) Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. Clin Ther 30:641–653CrossRefPubMedGoogle Scholar
  71. Perera V, Gross AS, Xu H, McLachlan AJ (2011) Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics. J Pharm Pharmacol 63:1161–1168CrossRefPubMedGoogle Scholar
  72. Perera V, Gross AS, McLachlan AJ (2012) Measurement of CYP1A2 activity: a focus on caffeine as a probe. Curr Drug Metab 13:667–678CrossRefPubMedGoogle Scholar
  73. Rao N, Chou T, Ventura D, Abramowitz W (2005) Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study. In Clin Ther 27:1596–1606CrossRefGoogle Scholar
  74. Shirasaka Y, Sager JE, Lutz JD, Davis C, Isoherranen N (2013) Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions. Drug Metab Dispos 41:1414–1424CrossRefPubMedPubMedCentralGoogle Scholar
  75. Silvasti M, Karttunen P, Tukiainen H, Kokkonen P, Hanninen U, Nykanen S (1987) Pharmacokinetics of dextromethorphan and dextrorphan: a single dose comparison of three preparations in human volunteers. Int J Clin Pharmacol Ther Toxicol 25:493–497PubMedGoogle Scholar
  76. Turpault S, Brian W, Van Horn R, Santoni A, Poitiers F, Donazzolo Y, Boulenc X (2009) Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. In Br J Clin Pharmacol 68:928–935CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Natacha Lenuzza
    • 1
  • Xavier Duval
    • 2
    • 3
  • Grégory Nicolas
    • 4
  • Etienne Thévenot
    • 1
  • Sylvie Job
    • 1
  • Orianne Videau
    • 4
  • Céline Narjoz
    • 5
    • 6
  • Marie-Anne Loriot
    • 5
    • 6
  • Philippe Beaune
    • 5
    • 6
  • Laurent Becquemont
    • 7
  • France Mentré
    • 3
  • Christian Funck-Brentano
    • 8
    • 9
  • Loubna Alavoine
    • 2
  • Philippe Arnaud
    • 10
  • Marcel Delaforge
    • 11
  • Henri Bénech
    • 4
  1. 1.CEA, LIST, Data Analysis and Systems Intelligence LaboratoryGif-sur-YvetteFrance
  2. 2.Clinical Investigation Center (CIC-1425)CHU Bichat Claude BernardParisFrance
  3. 3.INSERM, IAME, UMR1137, University Paris-Diderot, Sorbonne Paris CitéParisFrance
  4. 4.CEA, DSV, iBiTecS, Pharmacology and Immunoanalysis UnitGif-sur-YvetteFrance
  5. 5.Department of Biochemistry, Pharmacogenetics and Molecular Oncology UnitAssistance Publique des Hôpitaux de Paris, Hôpital Européen Georges PompidouParisFrance
  6. 6.University Paris Descartes, INSERM UMRS 1147, Sorbonne Paris CitéParisFrance
  7. 7.Clinical Research Unit EA2706 Paris sud-CHU BicêtreLe Kremlin BicêtreFrance
  8. 8.Department of Pharmacology and UMR ICAN 1166, Faculty of MedicineSorbonne University, UPMC Univ Paris 06ParisFrance
  9. 9.Department of Pharmacology and CIC-1421Assistance Publique des Hôpitaux de Paris, Pitié-Salpêtrière HospitalParisFrance
  10. 10.PharmacyCHU Bichat Claude BernardParisFrance
  11. 11.CEA, DSV, iBiTecS, UMR 8221, Bioenergetics, Structural Biology and Mechanisms UnitGif-sur-YvetteFrance

Personalised recommendations